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The mucoid exopolysaccharide (MEP or alginate) of Pseudomonas aeruginosa is thought to be a virulence
factor for this organism by virtue of its ability to suppress local host defense mechanisms. We purified MEP
from clinical isolates of mucoid P. aeruginosa, subjected it to degradation by ultrasonication, heat, alkali, and
alginase, and reacted it with monoclonal antibodies specific for MEP epitopes. Partial reversal or complete
abrogation of the inhibitory effects of alginate on human neutrophil random migration, chemotaxis, and hexose
monophosphate shunt activity and lymphocyte transformation were observed following most of these
treatments. Physicochemical analysis of degraded MEP revealed a positive correlation between changes in
molecular size and viscosity and loss of biological properties. The biological properties ofMEP were also shown
to be dependent on the structural integrity ofthe O-acetyl groups substituted for the mannuronic acid residues.
The results show that the capacity of MEP to suppress neutrophil and lymphocyte functions is dependent on
its acetyl content and the physical properties of large size and viscosity and may provide part of the explanation
for the propensity of mucoid P. aeruginosa to persist in the airways of patients with cystic fibrosis. These
findings highlight the important role ofMEP as one of the virulence factors in the pathogenesis of inflammatory
damage and subsequent pulmonary destruction in cystic fibrosis.
Pseudomonas aeruginosa, a ubiquitous gram-negative
aerobic bacillus found in soil and water habitats, is an
important cause of morbidity and mortality in patients with
cancer or bums and in immunocompromised patients (4, 9,
20, 26). While nonmucoid strains of P. aeruginosa are
generally responsible for these opportunistic infections, mu-
coid strains are usually isolated from patients with cystic
fibrosis (CF), in whom their emergence in the respiratory
tract heralds the onset of inexorable pulmonary deterioration
(12, 14, 17, 18, 28, 34). The reasons for the ability of mucoid
P. aeruginosa to persist in CF patients is unclear, but at least
two explanations, which are not mutually exclusive, have
been forwarded. One explanation concerns the propensity of
mucoid P. aeruginosa to adhere to the respiratory tract
epithelium and mucin of CF patients (6, 24, 31, 32).
Another explanation is centered on the antiphagocytic and
immunosuppressive properties of the mucoid exopolysac-
charide (MEP), also known as alginate, which is involved in
the evasion of host defense in the respiratory tract. Although
this contention is supported by a number of studies (2, 15,
19, 23, 25, 27, 33, 36, 38, 39), it is possible that contaminants
in some MEP preparations are responsible for the laboratory
observations. Moreover, only a minority of the strains
studied by Baltimore and Mitchell (2) showed decreased
phagocytosis of the mucoid compared with the nonmucoid
revertant bacteria. Furthermore, while some studies have
implicated a relationship between the chemical composition,
molecular size, and viscosity of MEP and its biological
activity (38), these studies have not examined this effect
directly on neutrophils and lymphocytes. In this study, we
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sought to answer this question by subjecting MEP to degra-
dation by physicochemical methods and an alginase enzyme
and by reacting it with specific monoclonal antibodies
(MAbs).
MATERIALS AND METHODS
Purification of MEP. The three clinical isolates of mucoid
P. aeruginosa used, IRL-1, IRL-2, and IRL-3, were origi-
nally obtained from Martyn Tilse and Theo Mollee of the
Department of Microbiology, Mater Public Hospital, South
Brisbane, Australia (22, 23). The isolates were stored in
aliquots in Protect Preservers (Sigma, St. Louis, Mo.) at
-70°C by the method of Feltham et al. (10). For MEP
production, a stock culture was first plated overnight on
blood agar and then streaked heavily on MacConkey agar
plates modified by the addition of 3% (vol/vol) glycerol to
enhance MEP secretion (8). After 4 days of culturing at 25°C,
surface growth was removed and placed in 25 volumes of
sterile 0.9% saline, and the suspension was stirred until a
uniform appearance was observed. The suspension was
centrifuged at 20,000 x g for 60 min, and the supernatant
was recentrifuged at the same speed for another 2 h. After
removal, the supematant was treated with the slow addition
of 3 volumes of 95% ethanol. The precipitate was recovered
by centrifugation at 3,000 x g for 30 min and subjected to
treatment with 95% ethanol twice and pure ethanol once.
Further purification of MEP (7) was accomplished by disso-
lution in 0.1 M Tris buffer (pH 7.4) at a concentration of 5
mg/ml and the addition of 1 mg of pronase (Sigma) per ml.
After incubation at 37°C for 48 h, the mixture was dialyzed
for 17 h against two changes of 40 volumes of distilled water
and centrifuged at 20,000 x g for 2 h to remove formal
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precipitates. The supernatant was removed, and sodium
acetate was added to a final concentration of 0.5%, after
which the supernatant was treated with 3 volumes of 95%
ethanol to precipitate alginate. After further treatments with
80%, 95%, and pure ethanol and ether, the supernatant was
dried in ether for the experiments. MEP so prepared was
checked for protein and nucleic acid contamination by
measuring the A280 and A260, respectively, with a spectro-
photometer (7), and the contamination was found to be
<0.5% for both. Lipopolysaccharide contamination was
found to be <0.01% by the Limulus amebocyte assay. This
highly purified MEP was used at a final concentration of
either 3 ,ug/ml for neutrophil locomotion and lymphocyte
transformation experiments or 30 ,ug/ml for neutrophil hex-
ose monophosphate (HMP) shunt experiments (23).
Physical degradation. Physical degradation of the purified
MEP was accomplished by ultrasonication in an ice bath for
30 min with a Branson sonicator at setting no.6 or by heating
of MEP in a boiling water bath (100°C) for 30 min. Degrada-
tion of MEP was verified by the detection of changes in
viscosity and size. The viscosity of the MEP solution (120
p,g/ml) was measured in a viscosity meter (Contraves, Zur-
ich, Switzerland) by use of low-shear setting 30. The molec-
ular size was determined by introducing samples in 0.2 M
ammonium carbonate buffer (pH 8.6) into a Sepharose
CL-4B column (1.6 by 100 cm). The column flow rate was 30
ml/h. The void volume was measured by elution of blue
dextran 2000, and the bed volume was measured by elution
of acetone. The proportional elution volume was calculated
by standard practice (Gel Filtration Theory and Practice;
Pharmacia Fine Chemicals).
Chemical degradation. Chemical degradation of the puri-
fied MEP was accomplished with 1 and 2 N NaOH (60 min,
25°C), after which the pH was readjusted to 7.4 with 1 N
HCl. Degradation was verified by acetate determination via
gas chromatography. Acetate content was measured with
samples hydrolyzed in 0.1 M NH40H at 95°C for 5 h. The
samples contained isovaleric acid as an internal standard at
a sample/internal standard ratio of 10:1. After hydrolysis, 2
to 5 pl of the samples was applied to a Nukol fused-silica
capillary column (15 m by 0.53 mm [inner diameter]; Supelco
Inc., Bellefonte, Pa.) in a Hewlett-Packard 5880 gas chro-
matograph. The carrier gas was hydrogen at a flow rate of 20
ml/min, and detection was done by flame ionization. The
response to acetic and isovaleric acids was determined by
injection of known quantities of standards. This response
was used to calculate the milligrams of acetate per milligram
of alginic acid sample.
Preparation of alginase. Bacillus circulans was obtained
from the American Type Culture Collection, Rockville, Md.
(ATCC 15518), and grown in alginate-yeast extract medium
at 26°C with vigorous aeration (7, 16). After 3 to 4 days, the
medium was centrifuged at 8,000 x g and 4°C for 20 min, and
the supernatant was removed and concentrated 10-fold with
Centriprep-10 (Amicon). Alginase was precipitated from the
concentrate by the addition of ammonium sulfate (70%
saturation), and the precipitate was collected by centrifuga-
tion at 20,000 x g for 30 min at 4°C. It was dissolved in 10
mM Tris hydrochloride (pH 7.4) and dialyzed overnight
against Tris hydrochloride.
This crude preparation of alginase was further purified by
chromatography in a DEAE-Sephacel column (2.5 by 20 cm;
Sigma). The alginase was eluted with Tris buffer containing
an NaCl gradient (0.05 to 0.5 M), and the fractions were
collected, dialyzed against distilled water overnight, and
lyophilized by the method of Eftekhar and Speert (7).
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FIG. 1. Reversal by treatment with ultrasonication (a) and heat
(b) of the inhibitory effects of MEP on neutrophil locomotion and
lymphocyte transformation by phytohemagglutinin (PHA), con-
canavalin A (Con A), and pokeweed mitogen (PWM). Symbols: 0,
native alginate; 1, treated alginate. Results represent the mean ±
standard error of the mean for three experiments, each performed in
triplicate. Similar results were obtained with alginate derived from
two other clinical isolates. *, P < 0.05.
The specific activity of the alginase was quantified by the
periodate-thiobarbiturate assay (43). In brief, 0.5 ,ul of en-
zyme was added to 0.5 ml of sodium alginate (2.5 mg/ml) at
room temperature. Samples of 50 pl were removed at 10-min
intervals for up to 60 min and added to 0.25 ml of 0.25 N
HIO4 in 0.125 N H2SO4. After 20 min at room temperature
with shaking, 0.5 ml of 2% sodium arsenite in 0.5 N HCl was
added, and the mixture was allowed to stand for 2 min; then,
2 ml of 0.3% thiobarbituric acid (pH 2.0) was added, and the
mixture was stirred and heated to 100°C for 10 min. On
cooling, the optical density was measured at 549 nm in an
LKB spectrophotometer. One unit of alginase activity was
defined as the amount of enzyme required to liberate 1 nmol
of 1-formylpyruvate per min per ml (0.01 ,umol produces an
increase in the optical density of 0.29). The protein concen-
tration was determined by the method of Lowry et al. (21),
so that alginase activity could be expressed as units per
milligram of protein. The enzyme concentration was ad-
justed to 500 U/ml for the experiments.
Preparation of MAbs. MAbs were prepared against P.
aeruginosa MEP in mice by standard methods. In brief,
animals were immunized with whole bacteria (108 CFU per
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FIG. 2. Reversal of the inhibitory effects of MEP on neutrophil
function (a) and lymphocyte transformation (b) by degradation with
sodium hydroxide. Symbols: LI, native alginate; 1, alginate de-
graded with 1 N NaOH; *, alginate degraded with 2 N NaOH.
Results represent the mean + standard error of the mean for three
experiments, each performed in triplicate. Similar results were
obtained with alginate derived from two other clinical isolates. *, P
< 0.05; **, P < 0.001. Abbreviations are as defined in the legend to
Fig. 1.
animal) or purified MEP (50 ,ug per mouse) at multiple times.
Spleen cells were recovered 3 days after the final immuni-
zation and fused with myeloma cell lines (SP/2 for 8/5/31.3
and P3X for M/K/16.2) by use of polyethylene glycol.
Supematants were screened for antibodies in an enzyme-
linked immunosorbent assay (ELISA) (5), and positive wells
were cloned twice by limiting dilution. Wells were re-
screened in the ELISA, and the hybridoma cells were
transformed to progressively larger cell culture volumes to
produce sufficient amounts for antibody testing in an op-
sonophagocytic assay (1). The antibodies were then classi-
fied as opsonic or nonopsonic on the basis of this in vitro
activity. They were stored as culture supematants at -70°C
until use. The two selected for use in these experiments were
designated 8/5/31.3 and M/K/16.2. The former mediates
opsonic killing of mucoid P. aeruginosa in the presence of
human neutrophils and complement, while the latter does
not mediate opsonic killing and binds to a different epitope
on the MEP antigen. Both MAbs are of the immunoglobulin
Neutrophils
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FIG. 3. Reversal of the inhibitory effects of MEP (Fig. 2) by
degradation with alginase. Symbols: 0, native alginate; 1, alginate
treated with native alginase; *, alginate treated with heat-inacti-
vated alginase. Results represent the mean + standard error of the
mean for three experiments, each performed in triplicate. Similar
results were obtained with alginate derived from two other clinical
isolates. *, P < 0.001. Abbreviations are as defined in the legend to
Fig. 1.
G2b class. A dilution of 1:10 was used for these MAb culture
supernatants in these experiments. These MAbs have been
well characterized in previous studies (29, 30, 35).
Isolation of lymphocytes and neutrophils. About 30 to 50 ml
of blood was obtained from healthy donors and layered
onto Mono-Poly Resolving Medium (Flow Laboratories,
McLean, Va.) (11). Centrifugation at 600 x g for 30 min
resulted in the formation of two leukocyte bands at the
interface. Mononuclear cells from the top band were washed
twice and resuspended in RPMI 1640 medium for the exper-
iments. The second band, containing neutrophils of >97%
purity (11), was removed, washed twice, and resuspended in
medium 199 or Dulbecco's phosphate-buffered saline for the
experiments.
Neutrophil locomotion. The movement of neutrophils un-
der agarose was monitored as previously described (37). In
Brief, 3 ml of double-strength medium 199 containing 20%
heat-inactivated fetal calf serum was mixed with 3 ml of 2%
agarose solution, and the mixture was poured into tissue
culture plates (60 by 15 mm). Wells 2 mm in diameter and 2.5
mm apart were punched in sets of three. The middle well
received 5 p1l of neutrophil suspension (with or without
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MEP) at a cell concentration of 4 x 107/ml, the outer well
received a chemoattractant, and the inner well received
medium 199 only. The chemoattractant was made by incu-
bating 107 Candida albicans cells with 2 ml of fresh human
serum for 30 min at 37°C, centrifuging the mixture at 1,000 x
g for 10 min, and removing the activated serum for use. The
agarose plates were kept in a 5% C02-air atmosphere with
high humidity for 2 h, and the distances moved towards the
inner well (random movement) and the outer well (chemo-
taxis) were measured with the aid of an eyepiece grid in an
inverted microscope. All experiments were performed in
triplicate.
HMP shunt activity. Stimulated neutrophils metabolize
glucose via the HMP shunt to generate oxygen-derived free
radicals. HMP shunt activity was quantified as the conver-
sion of 14C-1-glucose to 14C02 (42). In brief, 2 x 106
neutrophils per ml in Dulbecco's phosphate-buffered saline
was treated with 0.1 ig of PMA per ml in a total volume of
1 ml at 37°C for 45 min. Then, 1 N hydrochloric acid was
added to drive out any dissolved 14C02, which was captured
in 5 N sodium hydroxide and quantitated in a scintillation
spectrophotometer. All experiments were performed in trip-
licate.
Mitogen-induced lymphocyte transformation. The lectins
phytohemagglutinin A, pokeweed mitogen, and concanava-
lin A were purchased from Wellcome, Sydney, Australia;
GIBCO, Grand Island, N.Y.; and Calbiochem-Behring, Syd-
ney, Australia, respectively. They were used at optimal
concentrations of 0.5 ,ug/ml, 1/100 dilution, and 12.5 ,ug/ml,
respectively. To each microtiter well was delivered 0.1 ml of
RPMI 1640 medium containing 2 x 106 lymphocytes per ml,
0.5 ml of lectin, and 0.5 ml of alginate or medium only as
previously described (41). The microtiter trays were kept at
37°C in a 5% C02-air atmosphere and high humidity for 72 h.
At 6 h prior to harvesting, 1 ,uCi of 3H-thymidine was added
to each culture. The cultures were aspirated onto glass fiber
filter paper with a Skatron harvester, and 3H-thymidine
uptake was determined by liquid scintillation spectroscopy.
All experiments were performed in triplicate.
Statistical analyses. The one-way analysis of variance, the
Newman-Keuls test for multiple comparisons, and the Pear-
son correlation test were used for statistical analyses.
Neutrophils
* *
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FIG. 4. Reversal by treatment with specific MAbs of the inhibi-
tory effects of MEP (Fig. 2). Symbols: El, native alginate; 1,
alginate treated with native MAb 8/5/31.3; *, alginate treated with
heat-inactivated MAb 8/5/31.3; 0, alginate treated with native MAb
M/K/16.2; U, alginate treated with heat-inactivated MAb M/K/16.2.
Results represent the mean ± standard error of the mean for three
experiments, each performed in triplicate. Similar results were
obtained with alginate derived from two other clinical isolates. *, P
< 0.001. Abbreviations are as defined in the legend to Fig. 1.
RESULTS
Effect of physical degradation. We first subjected MEP to
degradation by ultrasonication in an ice bath for 30 min with
the probe tip of the Branson sonicator set at 6. As shown in
Fig. la, ultrasonicated MEP had fewer inhibitory effects on
neutrophil locomotion and lymphocyte transformation than
did native MEP.
Similarly, heating of MEP at 100°C for 30 min resulted in
the partial abrogation of its inhibitory effects on neutrophil
locomotion and lymphocyte transformation, as shown in
Fig. lb.
Effect of chemical degradation. We next subjected MEP to
chemical treatment with either 1 or 2 N NaOH for 60 min at
room temperature, after which the pH was readjusted to 7.4
with 1 N HCI. The results (Fig. 2) showed a significant
stepwise abrogation of the inhibitory activity of MEP by
NaOH degradation. The acetate level following treatment
with 1 N NaOH was not determined, but there was likely
only a partial removal of acetate from this sample, inasmuch
as it retained some inhibitory capacity with regard to neu-
trophil and lymphocyte functions (Fig. 2). Complete removal
of acetate by 2 N NaOH, as documented by gas chromato-
graphic analysis, resulted in complete abrogation of the
inhibitory activity of MEP. Such treatment also reduced the
viscosity of MEP from 3.5 to 0.9 cP. In addition, this
treatment resulted in only a small change in the molecular
size, as reflected in a broadening of the peak of MEP eluting
from the sizing column and a resultant slight downward shift
of the proportional elution volume. However, <25% ofMEP
shifted downward in molecular size.
Effect of alginase. The alginase enzyme derived from B.
circulans ATCC 1558 was used to degrade MEP for the next
set of experiments. After incubation of MEP with alginase
(300 U/ml) for 30 min at 37°C, the mixture was added to
either neutrophil or lymphocyte cultures. Controls contained
MEP treated with heat-inactivated enzyme (60°C for 2 h).
The results (Fig. 3) showed that specific degradation ofMEP
by the native but not the heat-inactivated enzyme signifi-
cantly reduced the inhibitory activity of MEP.
Effect of MAbs. In the next set of experiments, we used
two MAbs directed against epitopes on the MEP molecule;
one was opsonic and the other was nonopsonic. Both MAbs
were able to reverse the inhibitory effects ofMEP (Fig. 4). In
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TABLE 1. Correlation analysis of the molecular size, viscosity, and biological activity of native and degraded MEPa
Molecular size Biological activity (% inhibition of:)
MEP ~~~~~~~~~~~~~~~~~~~ViscosityMEP Proportional Mol wt (cP) Neutrophil Lymphocyte
elution vol chemotaxis transformation
Native 0.025 >2,000,000 3.5 48.3 54.2
Heated 0.175 687,000 1.6 38.4 38.3
Ultrasonicated 0.425 115,000 1.1 27.4 33.0
Alginase treated 0.500 67,000 0.8 13.0 3.1
a r values were as follows: size versus viscosity, 0.995; size versus chemotaxis, 0.875; size versus transformation, 0.806; viscosity versus chemotaxis, 0.882;
and viscosity versus transformation, 0.833.
contrast, heat-inactivated (60°C for 2 h) MAbs had no effect
on the inhibitory activity of MEP (Fig. 4).
Size, viscosity, and biological activity. Finally, we per-
formed a correlation analysis of the biological activity,
molecular size, and viscosity of MEP treated with heat,
ultrasonication, and alginase. The results (Table 1) showed a
significant correlation among all these variables; i.e., the
larger the size, the higher the viscosity, and the greater the
inhibitory effects of MEP on neutrophil chemotaxis and
lymphocyte transformation.
DISCUSSION
P. aeruginosa MEP is an acetylated polymer of 1-D-
mannuronic and a-L-guluronic acids. The two uronic acids of
MEP are arranged in different ways within the large alginate
molecule to form block structures (8, 12, 34). The relative
proportions of the two uronic acids and the presence of
O-acetyl groups are major determinants of its physicochem-
ical properties and its resistance to degradation. The ability
of MEP to form a gel with water is postulated as a mecha-
nism of protecting the bacterium from the periodic cycles of
dehydration in its aquatic habitat (12, 14, 28, 34). Another
biological role for MEP may be to enhance the capacity of
the bacterium to adhere to substrates in its habitat (21a).
Thus, in the evolutionary context, the superb adaptation of
mucoid P. aeruginosa to the respiratory tracts of CF patients
may be regarded as a form of biological serendipity.
The results of the present study show that purified P.
aeruginosa MEP is partially degraded by physical factors
such as ultrasonication and heat and that this degradation
results in a decrease in its capacity to inhibit neutrophil and
lymphocyte responses. It is more susceptible to degradation
by alkali in the form of sodium hydroxide, which has been
shown to cause deacetylation of the exopolysaccharide (34,
38, 40). Our data also show that the biological effects ofMEP
can be altered by degradation with the alginase enzyme
derived from B. circulans. This enzyme acts on mannuronic
residues and O-acetyl groups to alter the block structures of
the exopolysaccharide (7, 16). In addition, our data show
that MAbs raised against MEP epitopes (29, 30, 35) are able
to block the inhibitory effects of MEP on neutrophil and
lymphocyte responses. Furthermore, heat inactivation of the
alginase enzyme and the two MAbs prevented the destruc-
tion of the inhibitory effects of alginate. Similar results were
obtained with purified MEP derived from two other clinical
isolates of P. aenrginosa (data not shown). These results
suggest that the capacity of MEP to suppress neutrophil and
lymphocyte functions is specific to the molecule itself and is
not due to contaminants. The correlation between the bio-
logical properties of MEP and its viscosity and molecular
size confirms and extends the work of Simpson et al. (38) and
Gamer et al. (13) and is consistent with a recent report by
Bayer et al. (3).
Taken together, the data from this and other studies
provide a plausible explanation for the propensity of mucoid
P. aeruginosa to persist in the respiratory tracts of CF
patients. A suggested mechanism for the pathogenesis of
pulmonary tissue injury involves the change to a mucoid P.
aeruginosa phenotype, which allows the bacteria to evade
phagocytic killing and multiply in great profusion within the
lumen of the airways. Since MEP is confined to the airway
lumen, general immunological responses within the lung
parenchyma and circulation remain intact, so that phago-
cytic cells continue to enter the lung, being drawn by
bacteria and host-derived chemotactic molecules. The accu-
mulation of large quantities of pseudomonal toxins, en-
zymes, and metabolites in the airway lumen and their
subsequent diffusion result in damage to the adjacent lung
parenchyma. The diffusion of phagocyte-derived toxic en-
zymes and free radicals into the lung parenchyma causes
additional inflammatory damage. However, when the phago-
cytic cells finally reach the airways, they are unable to
eliminate the MEP-coated bacteria, which continue to mul-
tiply in great profusion to maintain the vicious cycle. This
sequence of events may account for the inexorable deterio-
ration of pulmonary function in CF patients colonized by
mucoid strains of P. aeruginosa.
In conclusion, these studies provide further insights into
the pathogenesis of persistent colonization by mucoid strains
of P. aeruginosa and subsequent progressive pulmonary
destruction. They also highlight the important role ofMEP in
this multifactorial process and endorse the development of
therapeutic and preventive measures aimed at this substance
as a strategy worthy of consideration. In this regard, alginate
lyase has been suggested by Russell and Gacesa (34) as a
therapeutic agent, alginase has been successfully used in the
treatment of experimental endocarditis in rabbits (3), and
alginate as a vaccine is now undergoing clinical trials.
Further stuidies along these lines will indicate whether this
strategy is correct.
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